DE2907778A1 - Verwendung von phosphatidylverbindungen in arzneimitteln gegen wahrnehmungs-, bewusstseins- und bewegungsstoerungen - Google Patents

Verwendung von phosphatidylverbindungen in arzneimitteln gegen wahrnehmungs-, bewusstseins- und bewegungsstoerungen

Info

Publication number
DE2907778A1
DE2907778A1 DE19792907778 DE2907778A DE2907778A1 DE 2907778 A1 DE2907778 A1 DE 2907778A1 DE 19792907778 DE19792907778 DE 19792907778 DE 2907778 A DE2907778 A DE 2907778A DE 2907778 A1 DE2907778 A1 DE 2907778A1
Authority
DE
Germany
Prior art keywords
acid
use according
fatty acid
phosphatidylic
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE19792907778
Other languages
German (de)
English (en)
Other versions
DE2907778C2 (cg-RX-API-DMAC7.html
Inventor
Kenichi Kashima
Akira Miyamoto
Tadashi Nakajima
Kyoji Rikimi
Yasuji Soda
Yoshikazu Soejima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Azwell Inc
Original Assignee
Nippon Shoji Kaisha Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shoji Kaisha Ltd filed Critical Nippon Shoji Kaisha Ltd
Publication of DE2907778A1 publication Critical patent/DE2907778A1/de
Application granted granted Critical
Publication of DE2907778C2 publication Critical patent/DE2907778C2/de
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE19792907778 1978-02-28 1979-02-28 Verwendung von phosphatidylverbindungen in arzneimitteln gegen wahrnehmungs-, bewusstseins- und bewegungsstoerungen Granted DE2907778A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2238578A JPS54117034A (en) 1978-02-28 1978-02-28 Treating agent for consciousness and perception motion disorder

Publications (2)

Publication Number Publication Date
DE2907778A1 true DE2907778A1 (de) 1979-08-30
DE2907778C2 DE2907778C2 (cg-RX-API-DMAC7.html) 1990-09-06

Family

ID=12081179

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19792907778 Granted DE2907778A1 (de) 1978-02-28 1979-02-28 Verwendung von phosphatidylverbindungen in arzneimitteln gegen wahrnehmungs-, bewusstseins- und bewegungsstoerungen

Country Status (4)

Country Link
US (1) US4263286A (cg-RX-API-DMAC7.html)
JP (1) JPS54117034A (cg-RX-API-DMAC7.html)
DE (1) DE2907778A1 (cg-RX-API-DMAC7.html)
NL (1) NL7901601A (cg-RX-API-DMAC7.html)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2464715A1 (fr) * 1979-09-14 1981-03-20 Lpb Ist Farm Utilisation de derives de glycerylphosphoryle dans la therapie des dyslipemies, des hepatites et des etats pathologiques analogues et compositions pharmaceutiques pour cette therapie
DE3228629A1 (de) * 1982-07-31 1984-02-02 Reifenrath, Rainer Richard Otto, Dr., 3104 Unterlüß Pharmazeutisches erzeugnis zur behandlung der atemwege und verfahren zu seiner herstellung
EP0040039B1 (en) * 1980-05-08 1984-08-01 Takeda Chemical Industries, Ltd. Ethylene glycol derivatives of ammonioethyl phosphate, their production and use
EP0147735A3 (en) * 1983-12-22 1985-11-27 A. Nattermann & Cie. Gmbh Pharmaceutical preparation for the therapeutic treatment of rheumatic diseases
EP0147741A3 (en) * 1983-12-22 1985-12-04 A. Nattermann & Cie. Gmbh Pharmaceutical composition with special 1,2-diacyl-glycero-3-phosphocholines for the treatment of diseases of the stomach and the intestines
WO1988007860A1 (en) * 1987-04-08 1988-10-20 Riace Establishment Pharmaceutical compositions for the treatment of cerebral psycho-organic syndromes
EP0389667A3 (en) * 1989-03-07 1990-10-10 Pharmacaps, Inc. Use of lecithin to restore olfaction and taste
WO1994003180A1 (en) * 1992-07-30 1994-02-17 Prime European Therapeuticals S.P.A. Pharmacologically active glycerophosphoderivatives
EP0656782A4 (en) * 1992-07-27 1995-09-06 Abbott Lab NUTRITIONAL PRODUCT FOR PEOPLE WITH NEUROLOGICAL LESIONS.
WO2005037848A3 (en) * 2003-10-22 2005-05-26 Enzymotec Ltd Glycerophospholipids containing omega-3 and omega-6 fatty acids
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
US7968112B2 (en) 2003-10-22 2011-06-28 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US8052992B2 (en) 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5566512A (en) * 1978-11-15 1980-05-20 Massachusetts Inst Technology Method and composition for treating difficulties by administration of choline or choline dissociating compound
JPS55115824A (en) * 1979-02-28 1980-09-06 Nippon Shoji Kk Remedy for clouding of consciousness and sensomobile disorder
US4677099A (en) * 1981-09-04 1987-06-30 Yeda Research And Development Co., Ltd. Medical processes employing a novel lipid fraction
IL63734A (en) * 1981-09-04 1985-07-31 Yeda Res & Dev Lipid fraction,its preparation and pharmaceutical compositions containing same
US4666893A (en) * 1983-02-15 1987-05-19 St. Thomas Institute Methods of inducing resistance to bacterial and viral infections
US4921706A (en) * 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US5011964A (en) * 1985-03-07 1991-04-30 Cornell Research Foundation, Inc. Novel diacylglycerophosphoric acid esters and use thereof as substrates in enzyme assays
IT1199972B (it) * 1985-05-08 1989-01-05 Lpb Ist Farm Composizioni farmaceutiche per la terapia di sindromi cerebrali involutive e del decadimento mentale
US4923854A (en) * 1986-01-22 1990-05-08 The Liposome Company, Inc. Solubilization of hydrophobic materials using lysophospholipid
US5759548A (en) * 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
IL118180A (en) * 1996-05-08 2000-12-06 Modus Biolog Membranes Ltd Pharmaceutical compositions comprising a phosphatidic acid (PA) enriched natural phospholipid preparation and the production of such preparation
US6495532B1 (en) * 1997-03-19 2002-12-17 Sky High, Llc Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
IL121322A (en) * 1997-07-16 2002-07-25 Modus Biolog Membranes Ltd Modular pharmacological preparation of the immune system based on fats and its preparation
US6949528B1 (en) 1998-03-18 2005-09-27 Goddard John G Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
AU1029500A (en) * 1998-08-29 2000-03-21 Miklos Ghyczy Pharmaceutical and/or diet product
US6592910B1 (en) * 1999-04-20 2003-07-15 Board Of Trustees, Southern Illinois University Methods of treating clinical diseases with isoflavones
CA2380640A1 (en) * 1999-08-18 2001-02-22 Kyowa Hakko Kogyo Co., Ltd. Hair-growing agent
US20060063738A1 (en) * 2000-02-28 2006-03-23 Sky High, Llc Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
US6683066B2 (en) 2001-09-24 2004-01-27 Yanming Wang Composition and treatment method for brain and spinal cord injuries
US7691417B2 (en) 2004-09-02 2010-04-06 Clemson University Research Foundation Tumor and mutation suppressing plant extract

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3772360A (en) * 1969-07-01 1973-11-13 Smithkline Corp Adamantyl substituted glycerophosphoryl(and phosphonyl)ethanolamines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Mitt. dt. pharm. Gesellsch., 33. Jg., Nr. 2, S. 35-36, 1963 *
RÖMPP: Chemie-Lexikon, 6. Aufl. Sp. 3630 u. 7. Aufl. S. 1946-1947, 1973 *
Seifen, Öle, Fette, Wachse, 96. Jg., S. 551-554, 1970 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2464715A1 (fr) * 1979-09-14 1981-03-20 Lpb Ist Farm Utilisation de derives de glycerylphosphoryle dans la therapie des dyslipemies, des hepatites et des etats pathologiques analogues et compositions pharmaceutiques pour cette therapie
EP0040039B1 (en) * 1980-05-08 1984-08-01 Takeda Chemical Industries, Ltd. Ethylene glycol derivatives of ammonioethyl phosphate, their production and use
DE3228629A1 (de) * 1982-07-31 1984-02-02 Reifenrath, Rainer Richard Otto, Dr., 3104 Unterlüß Pharmazeutisches erzeugnis zur behandlung der atemwege und verfahren zu seiner herstellung
EP0147735A3 (en) * 1983-12-22 1985-11-27 A. Nattermann & Cie. Gmbh Pharmaceutical preparation for the therapeutic treatment of rheumatic diseases
EP0147741A3 (en) * 1983-12-22 1985-12-04 A. Nattermann & Cie. Gmbh Pharmaceutical composition with special 1,2-diacyl-glycero-3-phosphocholines for the treatment of diseases of the stomach and the intestines
WO1988007860A1 (en) * 1987-04-08 1988-10-20 Riace Establishment Pharmaceutical compositions for the treatment of cerebral psycho-organic syndromes
EP0389667A3 (en) * 1989-03-07 1990-10-10 Pharmacaps, Inc. Use of lecithin to restore olfaction and taste
EP0656782A4 (en) * 1992-07-27 1995-09-06 Abbott Lab NUTRITIONAL PRODUCT FOR PEOPLE WITH NEUROLOGICAL LESIONS.
WO1994003180A1 (en) * 1992-07-30 1994-02-17 Prime European Therapeuticals S.P.A. Pharmacologically active glycerophosphoderivatives
WO2005037848A3 (en) * 2003-10-22 2005-05-26 Enzymotec Ltd Glycerophospholipids containing omega-3 and omega-6 fatty acids
AU2004282006B2 (en) * 2003-10-22 2010-04-15 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids
AU2004282006C1 (en) * 2003-10-22 2010-10-21 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
US7968112B2 (en) 2003-10-22 2011-06-28 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
EP2258377A3 (en) * 2003-10-22 2011-10-05 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids
US8052992B2 (en) 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
US8470345B2 (en) 2003-10-22 2013-06-25 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids

Also Published As

Publication number Publication date
DE2907778C2 (cg-RX-API-DMAC7.html) 1990-09-06
JPS623127B2 (cg-RX-API-DMAC7.html) 1987-01-23
US4263286A (en) 1981-04-21
NL7901601A (nl) 1979-08-30
JPS54117034A (en) 1979-09-11

Similar Documents

Publication Publication Date Title
DE2907778C2 (cg-RX-API-DMAC7.html)
DE69111642T2 (de) Gabapentin und dessen Derivate zur Behandlung neurodegenerativer Krankheiten.
DE69904208T2 (de) Antioxidative mischung bestehend aus acetyl l-carnitin und alpha-liponsäure
DE69632743T2 (de) Verfahren zur regulierung des vagaltonus
DE69230046T2 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
DE3338995C2 (cg-RX-API-DMAC7.html)
DE69828881T2 (de) Zusammensetzung zur linderung von störungen der stimmungslage bei gesunden individuen
DE69118859T2 (de) Behandlung von Schlafstörungen unter Verwendung bestimmter Antidepressiva, z.B. Nefazodon
DE2903558A1 (de) Therapeutisches verfahren zur behandlung von hyperlipoproteinaemie und hyperlipidaemie sowie arzneimittel zu seiner durchfuehrung
DE69027220T2 (de) Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen
DE10349979B4 (de) Medikamentöse gezielte lokale Lipolyse
DE102010028365A1 (de) Verwendung einer Phospholipid enthaltenden Zusammensetzung zur Entfernung von subkutanen Fettansammlungen
EP0752246A2 (de) Kappa-Opiate für entzündliche Darmerkrankungen
CH670952A5 (cg-RX-API-DMAC7.html)
DE3323264C2 (de) Arzneimittel zur Behandlung von vaskulären Erkrankungen
DE69937574T2 (de) Verwendung des pharmazeutischen präparates "histochrome" zur behandlung des akuten herzinfarkts und ischämischer herzerkrankungen
GB2045612A (en) Pharmaceutical compositions containing phosphatidic acids for the treatment of disorders of consciousness perception and movement
DE2514335A1 (de) Oral zu verabreichendes arzneimittel mit antiplasmin-inhibitorwirkung
DE2206570B2 (de) Verwendung von ( + ) - Catechin
DE2527552A1 (de) Mittel zur behandlung von krankheitszustaenden, die durch demyelierungsprozesse oder hypercholinergie bedingt werden
DE3916417A1 (de) Kombinationspraeparate enthaltend rifampicin und thioacetazon sowie gegebenenfalls isonicotinsaeurehydrazid als aktive wirkstoffe
DE3650735T2 (de) Verwendung von Cholin oder Cholin freisetzenden Verbindungen zur Verringerung der Empfingdung von Ermüdung
DE2660486C2 (de) Verwendung von 2-Hydroxymethyl-3,4,5-trihydroxypiperidin als Arzneimittel
DE3125512A1 (de) L-arginin-d,l-pyroglutamat als auf neuroedokrinem gebiet wirksames mittel
DE3873210T2 (de) Verwendung von benzylpyridin-derivaten zur herstellung eines arzneimittels zur behandlung der demenz.

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee